News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Synageva BioPharma (GEVA) Highlights Sebelipase Alfa And LAL Deficiency Data At The Lysosomal Disease Network (LDN) WORLD Symposium™



2/14/2014 8:57:40 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LEXINGTON, Mass.--(BUSINESS WIRE)--Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products for rare diseases, today announced sebelipase alfa and lysosomal acid lipase deficiency (LAL Deficiency) data from oral and poster presentations at the LDN WORLD Symposium being held February 11-13 in San Diego, California.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES